MoonLake Immunotherapeutics Future Growth
Future criteria checks 0/6
MoonLake Immunotherapeutics is forecast to grow earnings and revenue by 3% and 71.4% per annum respectively. EPS is expected to grow by 5.7% per annum. Return on equity is forecast to be -69.2% in 3 years.
Key information
3.0%
Earnings growth rate
5.7%
EPS growth rate
| Biotechs earnings growth | 0% |
| Revenue growth rate | 71.4% |
| Future return on equity | -69.2% |
| Analyst coverage | Good |
| Last updated | 02 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -145 | -224 | -174 | 8 |
| 12/31/2025 | N/A | -100 | -133 | -146 | 11 |
| 12/31/2024 | N/A | -71 | -75 | -42 | 12 |
| 12/31/2023 | N/A | -36 | -43 | -43 | N/A |
| 9/30/2023 | N/A | -46 | -42 | -42 | N/A |
| 6/30/2023 | N/A | -46 | -42 | -42 | N/A |
| 3/31/2023 | N/A | -43 | -51 | -51 | N/A |
| 12/31/2022 | N/A | -50 | -56 | -56 | N/A |
| 9/30/2022 | N/A | -58 | -59 | -59 | N/A |
| 6/30/2022 | N/A | -54 | -52 | -51 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MLTX N is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MLTX N is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MLTX N is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MLTX N is forecast to have no revenue next year.
High Growth Revenue: MLTX N is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MLTX N is forecast to be unprofitable in 3 years.